Mostrar el registro sencillo del ítem

dc.contributor.author
Alvar, Jorge  
dc.contributor.author
Alves, Fabiana  
dc.contributor.author
Bucheton, Bruno  
dc.contributor.author
Burrows, Louise  
dc.contributor.author
Büscher, Philippe  
dc.contributor.author
Carrillo, Eugenia  
dc.contributor.author
Felger, Ingrid  
dc.contributor.author
Hübner, Marc P.  
dc.contributor.author
Moreno, Javier  
dc.contributor.author
Pinazo, Maria Jesus  
dc.contributor.author
Ribeiro, Isabela  
dc.contributor.author
Sosa-Estani, Sergio Alejandro  
dc.contributor.author
Specht, Sabine  
dc.contributor.author
Tarral, Antoine  
dc.contributor.author
Strub Wourgaft, Nathalie  
dc.contributor.author
Bilbe, Graeme  
dc.date.available
2021-10-04T18:04:19Z  
dc.date.issued
2020-03  
dc.identifier.citation
Alvar, Jorge; Alves, Fabiana; Bucheton, Bruno; Burrows, Louise; Büscher, Philippe; et al.; Implications of asymptomatic infection for the natural history of selected parasitic tropical diseases; Springer; Seminars in Immunopathology; 42; 3; 3-2020; 231-246  
dc.identifier.issn
1863-2297  
dc.identifier.uri
http://hdl.handle.net/11336/142513  
dc.description.abstract
Progress has been made in the control or elimination of tropical diseases, with a significant reduction of incidence. However, there is a risk of re-emergence if the factors fueling transmission are not dealt with. Although it is essential to understand these underlying factors for each disease, asymptomatic carriers are a common element that may promote resurgence; their impact in terms of proportion in the population and role in transmission needs to be determined. In this paper, we review the current evidence on whether or not to treat asymptomatic carriers given the relevance of their role in the transmission of a specific disease, the efficacy and toxicity of existing drugs, the Public Health interest, and the benefit at an individual level, for example, in Chagas disease, to prevent irreversible organ damage. In the absence of other control tools such as vaccines, there is a need for safer drugs with good risk/benefit profiles in order to change the paradigm so that it addresses the complete infectious process beyond manifest disease to include treatment of non-symptomatic infected persons.  
dc.format
application/pdf  
dc.language.iso
eng  
dc.publisher
Springer  
dc.rights
info:eu-repo/semantics/openAccess  
dc.rights.uri
https://creativecommons.org/licenses/by/2.5/ar/  
dc.subject
ASYMPTOMATIC  
dc.subject
CHAGAS DISEASE  
dc.subject
FILARIASIS  
dc.subject
HUMAN AFRICAN TRYPANOSOMIASIS  
dc.subject
LEISHMANIASIS  
dc.subject
MALARIA  
dc.subject.classification
Enfermedades Infecciosas  
dc.subject.classification
Ciencias de la Salud  
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD  
dc.title
Implications of asymptomatic infection for the natural history of selected parasitic tropical diseases  
dc.type
info:eu-repo/semantics/article  
dc.type
info:ar-repo/semantics/artículo  
dc.type
info:eu-repo/semantics/publishedVersion  
dc.date.updated
2021-09-07T15:01:24Z  
dc.journal.volume
42  
dc.journal.number
3  
dc.journal.pagination
231-246  
dc.journal.pais
Alemania  
dc.journal.ciudad
Berlin  
dc.description.fil
Fil: Alvar, Jorge. Drugs For Neglected Diseases Initiative; Suiza  
dc.description.fil
Fil: Alves, Fabiana. Drugs For Neglected Diseases Initiative; Suiza  
dc.description.fil
Fil: Bucheton, Bruno. Université Montpellier II; Francia  
dc.description.fil
Fil: Burrows, Louise. Drugs For Neglected Diseases Initiative; Suiza  
dc.description.fil
Fil: Büscher, Philippe. Institute Of Tropical Medicine; Bélgica  
dc.description.fil
Fil: Carrillo, Eugenia. Universidad Carlos III de Madrid. Instituto de Salud; España  
dc.description.fil
Fil: Felger, Ingrid. Swiss Tropical And Public Health Institute; Suiza  
dc.description.fil
Fil: Hübner, Marc P.. Universitat Bonn; Alemania  
dc.description.fil
Fil: Moreno, Javier. Universidad Carlos III de Madrid. Instituto de Salud; España  
dc.description.fil
Fil: Pinazo, Maria Jesus. Instituto de Salud Global de Barcelona; España  
dc.description.fil
Fil: Ribeiro, Isabela. Drugs For Neglected Diseases Initiative; Suiza  
dc.description.fil
Fil: Sosa-Estani, Sergio Alejandro. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Centro de Investigaciones en Epidemiología y Salud Pública. Instituto de Efectividad Clínica y Sanitaria. Centro de Investigaciones en Epidemiología y Salud Pública; Argentina  
dc.description.fil
Fil: Specht, Sabine. Drugs For Neglected Diseases Initiative; Suiza  
dc.description.fil
Fil: Tarral, Antoine. Drugs For Neglected Diseases Initiative; Suiza  
dc.description.fil
Fil: Strub Wourgaft, Nathalie. Drugs For Neglected Diseases Initiative; Suiza  
dc.description.fil
Fil: Bilbe, Graeme. Drugs For Neglected Diseases Initiative; Suiza  
dc.journal.title
Seminars in Immunopathology  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/http://link.springer.com/10.1007/s00281-020-00796-y  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1007/s00281-020-00796-y